Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: A randomized, double-blinded, double-dummy efficacy and safety study of budesonide–formoterol Spiromax® compared to budesonide–formoterol Turbuhaler® in adults and adolescents with persistent asthma

Fig. 2

Patient disposition. AE adverse event, BF budesonide–formoterol, ITT intent-to-treat, PP per protocol. aInclusion criteria not met, n = 25; exclusion criteria met, n = 6; withdrawal by patient, n = 6; AEs, n = 1; other, n = 16. bInclusion criteria not met, n = 5; withdrawal by patient, n = 5; randomization criteria not met, n = 2; AE, n = 1; lost to follow-up, n = 1; other, n = 52. cProtocol violation, n = 3; withdrawal by subject, n = 3; AE, n = 2; asthma exacerbation, n = 1; non-compliance, n = 1; other, n = 3. dProtocol violation, n = 5; withdrawal by subject, n = 3; AE, n = 2; lost to follow-up, n = 2; non-compliance, n = 1; other, n = 5. eThree patients who were randomized to the BF Turbuhaler 200/6 mcg did not receive treatment (due to randomization error, ‘withdrawal by subject’, ‘other’ reasons; each, n = 1)

Back to article page